← Back to guidelines
Cardiology53 papers

Localized hereditary cardiac amyloidosis

Last edited: 4/15/2026

Overview

Localized hereditary cardiac amyloidosis, often caused by mutations in the transthyretin (TTR) gene, leads to the deposition of amyloid fibrils in the heart, affecting cardiac function. Gastrointestinal manifestations are common but often misdiagnosed due to their nonspecific nature 1.

Diagnosis

  • Clinical Red Flags: Suspect hereditary transthyretin amyloidosis (ATTRv) when gastrointestinal symptoms are accompanied by cardiac involvement or other systemic manifestations 1.
  • Recommended Tests:
  • - Electrophysiological Studies: Including electrocardiography (ECG) and echocardiography to assess cardiac function and structure 1. - Biopsy: Cardiac biopsy for definitive diagnosis, though often invasive 1. - Genetic Testing: Identify specific TTR mutations 1.
  • Diagnostic Suspicion: Increased awareness among gastroenterologists and multidisciplinary teams is crucial for early detection 1.
  • Management

  • First-Line Treatments:
  • - TTR Stabilizers: Drugs like tafamidis or diflunisal to stabilize TTR and reduce amyloid deposition 1.
  • Adjunctive Treatments:
  • - Symptomatic Management: Address specific symptoms such as heart failure with standard therapies (e.g., diuretics, ACE inhibitors) 1. - Multidisciplinary Care: Involvement of cardiologists, gastroenterologists, and geneticists for comprehensive management 1.

    Special Populations

  • Limited Data: Specific management guidelines for pregnancy, pediatrics, and elderly patients are not detailed in the provided abstracts 1.
  • Comorbidities: Management should consider overlapping symptoms and treatments for comorbid conditions, emphasizing a multidisciplinary approach 1.
  • Key Recommendations

  • Suspect ATTRv in Patients with Gastrointestinal Symptoms and Cardiac Involvement: Early suspicion and referral to specialized centers are critical for timely diagnosis (Evidence: Expert opinion) 1.
  • Utilize TTR Stabilizers for Treatment: Implement tafamidis or diflunisal to manage disease progression (Evidence: Moderate) 1.
  • Enhance Multidisciplinary Team Involvement: Increase awareness and collaboration among gastroenterologists and cardiologists to improve diagnostic accuracy and patient outcomes (Evidence: Expert opinion) 1.
  • References

    1 Cappello M, Barbara G, Bellini M, Consalvo D, Di Sabatino A, Marasco G et al.. Identification and management of gastrointestinal manifestations of hereditary transthyretin amyloidosis: Recommendations from an Italian group of experts. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2024. link

    Original source

    1. [1]
      Identification and management of gastrointestinal manifestations of hereditary transthyretin amyloidosis: Recommendations from an Italian group of experts.Cappello M, Barbara G, Bellini M, Consalvo D, Di Sabatino A, Marasco G et al. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver (2024)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG